Astria Therapeutics (NASDAQ:ATXS) Issues Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Astria Therapeutics (NASDAQ:ATXS) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05), Yahoo Finance reports.

Astria Therapeutics Trading Up 7.6 %

ATXS traded up $0.74 during trading on Tuesday, reaching $10.50. 138,510 shares of the company were exchanged, compared to its average volume of 740,774. Astria Therapeutics has a 52 week low of $4.26 and a 52 week high of $16.90. The firm has a 50 day moving average of $10.03 and a 200 day moving average of $11.38. The stock has a market cap of $576.59 million, a P/E ratio of -4.54 and a beta of 0.73.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on ATXS shares. TD Cowen started coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They set a “buy” rating and a $35.00 price target on the stock. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday. Oppenheimer raised their price objective on Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a report on Tuesday. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $25.20.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.